<DOC>
	<DOCNO>NCT02291614</DOCNO>
	<brief_summary>The purpose Phase 1 study determine AMG 211 give continous IV infusion safe tolerable adult subject advance gastrointestinal adenocarcinoma . The study conduct multiple site test increase dos AMG 211 . The safety subject monitor intensive assessment vital sign , electrocardiogram , physical examination , laboratory test . Efficacy assess usual imaging procedure interpretation .</brief_summary>
	<brief_title>A Phase 1 Study AMG 211 Subjects With Advanced Gastrointestinal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Informed consent provide 18 year old Advanced relapsed/refracted gastrointestinal adenocarcinoma At least 1 measurable tumor lesion Tumor tissue available willing undergo biopsy tumor lesion start treatment Adequate hematological , renal , liver function Body weight â‰¥ 45 kg Other inclusion criterion may apply Malignancy GI adenocarcinoma require current therapy Evidence uncontrolled systemic disease , active infection , Hepatitis B and/or C , HIV , history cardiac disease , history significant central nervous system ( CNS ) disease , history chronic autoimmune disease ( exception stable type 1 diabetes ) Major surgery within 28 day study day 1 Currently receive treatment another investigational device drug study , less 28 day since end treatment another investigational device drug study . Other investigational procedure participate study exclude . Exception criterion participation optional Imaging Study procedure relate study . Treatment chemotherapy , radiotherapy , immunotherapy , biologic , hormonal therapy cancer within 14 day prior study entry recover treatment Unresolved toxicities prior antitumor therapy Males Females reproductive potential , unwilling practice acceptable method effective birth control study 30 day receive last dose study drug Females pregnant , plan become pregnant , lactating/breastfeeding plan breastfeed study 30 day receive last dose study drug Other exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Oncology</keyword>
	<keyword>GI adenocarcinoma</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>